Numan is exploring new verticals.
What’s happening: The UK-based digital health company secured $60M in funding to enter women’s health and expand AI care pathways.
Root cause. Established as a men’s health clinic, Numan emphasizes hybrid care, pairing at-home diagnostics and medication with clinical support.
Treating over 650K people to date with ED pills, TRT, and weight loss drugs like Mounjaro, its revenue doubled YoY to $90M. Driven by demand for GLP-1s, it’s projecting $200M in revenue in 2025 as it preps international expansion, namely Greece.
Extended care. Seizing momentum, it’s entering hormonal health for reproductive and menopausal support while enhancing AI-powered services like early risk detection, personalized treatments, and lifestyle coaching.
As competitors like Hims & Hers and WeightWatchers eye menopause, Australia’s Eucalyptus expands across borders, and UK rival Manual wades into weight loss, addressing women’s care gaps will strengthen its position as a full-stack health platform.
Looking ahead: In a race to redefine care, Numan is pairing tech, trust, and treatment to extend its preventative reach.
